PMID- 23730409
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130605
LR  - 20211021
IS  - 1936-5233 (Print)
IS  - 1936-5233 (Electronic)
IS  - 1936-5233 (Linking)
VI  - 6
IP  - 3
DP  - 2013 Jun
TI  - RASSF1A Promoter Methylation Levels Positively Correlate with Estrogen Receptor 
      Expression in Breast Cancer Patients.
PG  - 297-304
AB  - The aim of this study was to investigate the relationship between the promoter 
      methylation in five cancer-associated genes and clinicopathologic features for 
      identification of molecular markers of tumor metastatic potential and hormone 
      therapy response efficiency in breast cancer. The methylation levels in 
      paraffin-embedded tumor tissues, plasma, and blood cells from 151 sporadic breast 
      cancer patients and blood samples of 50 controls were evaluated by quantitative 
      multiplex methylation-specific polymerase chain reaction. DNA methylation of 
      RAS-association domain family member 1 (RASSF1A), estrogen receptor 1 (ESR1), 
      cadherin 1, type 1, E-cadherin (CDH1), TIMP metallopeptidase inhibitor 3 (TIMP3) 
      and spleen tyrosine kinase (SYK) genes was detected in the tumors of 124, 19, 15, 
      15, and 6 patients with mean levels of 48.45%, 3.81%, 2.36%, 27.55%, and 10.81%, 
      respectively. Plasma samples exhibited methylation in the same genes in 25, 10, 
      15, 17, and 3 patients with levels of 22.54%, 17.20%, 22.87%, 31.93%, and 27.42%, 
      respectively. Cumulative methylation results confirmed different spectra in tumor 
      and plasma samples. Simultaneous methylation in tumors and plasma were shown in 
      less than 17% of patients. RASSF1A methylation levels in tumor samples 
      statistically differ according to tumor size (P = .029), estrogen receptor (ER) 
      and progesterone receptor (PR) status (P = .000 and P = .004), and 
      immunohistochemical subtype (P = .000). Moreover, the positive correlation was 
      found between RASSF1A methylation levels and percentage of cancer cells 
      expressing ER and PR. The direct relationship between RASSF1A promoter 
      methylation and expression of ER could aid the prognosis of hormonal therapy 
      response.
FAU - Kajabova, Viera
AU  - Kajabova V
AD  - Laboratory of Cancer Genetics, Cancer Research Institute of Slovak Academy of 
      Sciences, Bratislava, Slovakia.
FAU - Smolkova, Bozena
AU  - Smolkova B
FAU - Zmetakova, Iveta
AU  - Zmetakova I
FAU - Sebova, Katarina
AU  - Sebova K
FAU - Krivulcik, Tomas
AU  - Krivulcik T
FAU - Bella, Vladimir
AU  - Bella V
FAU - Kajo, Karol
AU  - Kajo K
FAU - Machalekova, Katarina
AU  - Machalekova K
FAU - Fridrichova, Ivana
AU  - Fridrichova I
LA  - eng
PT  - Journal Article
DEP - 20130601
PL  - United States
TA  - Transl Oncol
JT  - Translational oncology
JID - 101472619
PMC - PMC3660798
EDAT- 2013/06/05 06:00
MHDA- 2013/06/05 06:01
PMCR- 2013/06/01
CRDT- 2013/06/05 06:00
PHST- 2013/02/27 00:00 [received]
PHST- 2013/02/27 00:00 [revised]
PHST- 2013/03/18 00:00 [accepted]
PHST- 2013/06/05 06:00 [entrez]
PHST- 2013/06/05 06:00 [pubmed]
PHST- 2013/06/05 06:01 [medline]
PHST- 2013/06/01 00:00 [pmc-release]
AID - 13244 [pii]
AID - 10.1593/tlo.13244 [doi]
PST - epublish
SO  - Transl Oncol. 2013 Jun 1;6(3):297-304. doi: 10.1593/tlo.13244. Print 2013 Jun.